Topamax
Tuberous Sclerosis Complex-associated Refractory Seizures
Novartis PharmaceuticalsPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Tuberous Sclerosis Complex-associated Refractory Seizures cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NORCLOBAZAM Novartis Pharmaceuticals | Phase 3 | BB |
Valproic Acid Novartis Pharmaceuticals | Phase 3 | B |
Clonazepam Novartis Pharmaceuticals | Phase 3 | B |
Everolimus Novartis Pharmaceuticals | Phase 3 | B |
Zonisamide Novartis Pharmaceuticals | Phase 3 | B |
Clobazam Novartis Pharmaceuticals | Phase 3 | B |
PHENYTOIN Novartis Pharmaceuticals | Phase 3 | B |
Phenobarbital Novartis Pharmaceuticals | Phase 3 | CCC |
Same molecule, other indications
Topamax is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →